Literature DB >> 22316397

Changes in antipsychotic medication use after implementation of a Medicaid mental health carve-out in the US.

John Robst1.   

Abstract

BACKGROUND: Many Medicaid programmes now offer behavioural healthcare through managed care organizations. Medicaid programmes are concerned about carve-outs because the use of non-included services may rise, limiting the efficiencies anticipated with the implementation of managed care. There also exist concerns that patients with serious mental illness may receive reduced care through managed care and consequently have poorer outcomes.
OBJECTIVE: This study examined prescription drug utilization among Medicaid recipients with the implementation of a mental health carve-out plan in Florida. In particular, this study examined short-run changes in the utilization of antipsychotic medications among individuals diagnosed with schizophrenia or episodic mood disorders with the implementation of Prepaid Mental Health Plans (PMHPs) in Florida Medicaid.
METHODS: This study used Medicaid data from 38 counties in Florida that implemented the PMHP programme in 2005 and 2006. The sample was limited to individuals aged≤64 years who were continuously enrolled in Medicaid. Individuals were required to have at least two diagnoses of schizophrenia, episodic mood disorders, delusional disorders or other nonorganic disorders (three-digit International Classification of Diseases, Ninth Revision [ICD-9] code of 295-298). Five different outcome measures were examined on a monthly basis for the 6 months pre- and post-PMHP implementation: penetration; adherence; Medicaid expenditures for antipsychotics; polypharmacy (multiple antipsychotic medications); and whether dosing was within guidelines. Generalized estimating equations were used to estimate associations between individual and insurance characteristics, and the outcome variables. The analyses were conducted using SAS procedure GENMOD. Empirical (robust) standard errors were calculated to account for repeated observations on the same individual.
RESULTS: There were 153,720 monthly observations for the 12,810 people in the sample. Seventy-four percent of the sample was aged between 21 and 54 years, while 65% were female, 30% White, 14% Black and 44% Hispanic. The large proportion of Hispanics stems from the introduction of the PMHP programme in Dade County (Miami). The results indicate the implementation of the PMHP was associated with increased penetration, but reduced adherence, polypharmacy and expenditures by the Medicaid agency. There was no change in the likelihood of prescriptions being written within recommended dosage ranges.
CONCLUSION: The introduction of the PMHP was associated with short-run changes in medication utilization among individuals with serious mental illness.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22316397     DOI: 10.2165/11539830-000000000-00000

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  27 in total

1.  Best practices: dissemination of guidelines for the treatment of major depression in a managed behavioral health care network.

Authors:  F Azocar; B D Cuffel; W Goldman; J McCulloch
Journal:  Psychiatr Serv       Date:  2001-08       Impact factor: 3.084

2.  How does managed care do it?

Authors:  D M Cutler; M McClellan; J P Newhouse
Journal:  Rand J Econ       Date:  2000

3.  Medication treatment patterns for adults with schizophrenia in Medicaid managed care in Colorado.

Authors:  Neal T Wallace; Joan R Bloom; Teh-Wei Hu; Anne M Libby
Journal:  Psychiatr Serv       Date:  2005-11       Impact factor: 3.084

4.  Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004.

Authors:  Todd P Gilmer; Christian R Dolder; David P Folsom; William Mastin; Dilip V Jeste
Journal:  Psychiatr Serv       Date:  2007-07       Impact factor: 3.084

5.  Assessment of compliance with antipsychotic treatment and resource utilization in a Medicaid population.

Authors:  Michael Eaddy; Amy Grogg; Julie Locklear
Journal:  Clin Ther       Date:  2005-02       Impact factor: 3.393

6.  Changes in the process of care for Medicaid patients with schizophrenia in Utah's Prepaid Mental Health Plan.

Authors:  M K Popkin; N Lurie; W Manning; J Harman; A Callies; D Gray; J Christianson
Journal:  Psychiatr Serv       Date:  1998-04       Impact factor: 3.084

7.  Antipsychotic medication adherence: is there a difference between typical and atypical agents?

Authors:  Christian R Dolder; Jonathan P Lacro; Laura B Dunn; Dilip V Jeste
Journal:  Am J Psychiatry       Date:  2002-01       Impact factor: 18.112

8.  Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change.

Authors:  Stephen B Soumerai; Fang Zhang; Dennis Ross-Degnan; Daniel E Ball; Robert F LeCates; Michael R Law; Tom E Hughes; Daniel Chapman; Alyce S Adams
Journal:  Health Aff (Millwood)       Date:  2008-04-01       Impact factor: 6.301

9.  The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003.

Authors:  Anthony F Lehman; Julie Kreyenbuhl; Robert W Buchanan; Faith B Dickerson; Lisa B Dixon; Richard Goldberg; Lisa D Green-Paden; Wendy N Tenhula; Daniela Boerescu; Cenk Tek; Neil Sandson; Donald M Steinwachs
Journal:  Schizophr Bull       Date:  2004       Impact factor: 9.306

10.  Olanzapine versus risperidone in the treatment of schizophrenia : a comparison of costs among Texas Medicaid recipients.

Authors:  Karen L Rascati; Michael T Johnsrud; M Lynn Crismon; Maureen J Lage; Beth L Barber
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

View more
  1 in total

1.  Second-generation antipsychotics cause a rapid switch to fat oxidation that is required for survival in C57BL/6J mice.

Authors:  Candice M Klingerman; Michelle E Stipanovic; Mohammad Bader; Christopher J Lynch
Journal:  Schizophr Bull       Date:  2013-01-17       Impact factor: 9.306

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.